 |
|
Health and Economic Benefits of Increased  -Blocker Use Following Myocardial Infarction
Kathryn A. Phillips, PhD;
Michael G. Shlipak, MD, MPH;
Pam Coxson, PhD;
Paul A. Heidenreich, MD, MS;
M. G. Myriam Hunink, PhD;
Paula A. Goldman, MPH;
Lawrence W. Williams, MS;
Milton C. Weinstein, PhD;
Lee Goldman, MD, MPH
JAMA. 2000;284:2748-2754.
Context  -Blockers are underused in patients who have myocardial infarction (MI), despite the proven efficacy of these agents. New evidence indicates that -blockers can have benefit in patients with conditions that have been considered relative contraindications. Understanding the consequences of underuse of -blockers is important because of the implications for current policy debates over quality-of-care measures and Medicare prescription drug coverage.
Objective To examine the potential health and economic impact of increased use of -blockers in patients who have had MI.
Design and Setting We used the Coronary Heart Disease (CHD) Policy Model, a computer-simulation Markov model of CHD in the US population, to estimate the epidemiological impact and cost-effectiveness of increased -blocker use from current to target levels among survivors of MI aged 35 to 84 years. Simulations included 1 cohort of MI survivors in 2000 followed up for 20 years and 20 successive annual cohorts of all first-MI survivors in 2000-2020. Mortality and morbidity from CHD were derived from published meta-analyses and recent studies. This analysis used a societal perspective.
Main Outcome Measures Prevented MIs, CHD mortality, life-years gained, and cost per quality-adjusted life-year (QALY) gained in 2000-2020.
Results Initiating -blocker use for all MI survivors except those with absolute contraindications in 2000 and continuing treatment for 20 years would result in 4300 fewer CHD deaths, 3500 MIs prevented, and 45,000 life-years gained compared with current use. The incremental cost per QALY gained would be $4500. If this increase in -blocker use were implemented in all first-MI survivors annually over 20 years, -blockers would save $18 million and result in 72,000 fewer CHD deaths, 62,000 MIs prevented, and 447,000 life-years gained. Sensitivity analyses demonstrated that the cost-effectiveness of -blocker therapy would always be less than $11,000 per QALY gained, even under unfavorable assumptions, and may even be cost saving. Restricting -blockers only to ideal patients (those without absolute or relative contraindications) would reduce the epidemiological impact of -blocker therapy by about 60%.
Conclusions Our simulation indicates that increased use of -blockers after MI would lead to impressive gains in health and would be potentially cost saving.
Author Affiliations: Department of Clinical Pharmacy, Institute for Health Policy Studies, and Center of Excellence on Health Care Markets and Managed Care (Dr Phillips) and Department of Medicine (Drs Shlipak, Coxson, and L. Goldman), University of California, San Francisco; San Francisco Veterans Affairs Medical Center (Dr Shlipak); Palo Alto VA Health Care System and Department of Medicine, Stanford University, Palo Alto, Calif (Dr Heidenreich); Department of Health Policy and Management, Harvard School of Public Health, Boston, Mass (Drs Hunink and Weinstein, Ms P. Goldman and Mr Williams); and Erasmus University Medical Center, Rotterdam, The Netherlands (Dr Hunink).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
December 6, 2000
JAMA. 2000;284(21):2803.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis
Scheetz et al.
J Antimicrob Chemother 2009;63:816-825.
ABSTRACT
| FULL TEXT
A Randomized Trial of Direct-to-Patient Communication to Enhance Adherence to {beta}-Blocker Therapy Following Myocardial Infarction
Smith et al.
Arch Intern Med 2008;168:477-483.
ABSTRACT
| FULL TEXT
Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease
Newby et al.
Circulation 2006;113:203-212.
ABSTRACT
| FULL TEXT
Medicare and Cost-Effectiveness Analysis
Neumann et al.
NEJM 2005;353:1516-1522.
FULL TEXT
Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes
Rosen et al.
ANN INTERN MED 2005;143:89-99.
ABSTRACT
| FULL TEXT
Pursuing integration of performance measures into electronic medical records: beta-adrenergic receptor antagonist medications
Weiner et al.
Qual Saf Health Care 2005;14:99-106.
ABSTRACT
| FULL TEXT
Evidence-Based Therapies for Myocardial Infarction: Secular Trends and Determinants of Practice in the Community
Perschbacher et al.
Mayo Clin Proc. 2004;79:983-991.
ABSTRACT
Prognostic Value of Pharmacological Stress Echocardiography Is Affected by Concomitant Antiischemic Therapy at the Time of Testing
Sicari et al.
Circulation 2004;109:2428-2431.
ABSTRACT
| FULL TEXT
The Business Case for Quality: Combining Medical Literature Research with Health Plan Data to Establish Value for Nonclinical Managers
Fetterolf and West
American Journal of Medical Quality 2004;19:48-55.
ABSTRACT
Patient Safety Is Not Enough: Targeting Quality Improvements To Optimize the Health of the Population
Woolf
ANN INTERN MED 2004;140:33-36.
ABSTRACT
| FULL TEXT
Risk Factors and Secondary Prevention in Women with Heart Disease
Shlipak et al.
ANN INTERN MED 2003;139:954-955.
FULL TEXT
Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada
Johnson et al.
J Am Coll Cardiol 2003;42:1438-1445.
ABSTRACT
| FULL TEXT
Use of Continuous Quality Improvement to Increase Use of Process Measures in Patients Undergoing Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial
Ferguson et al.
JAMA 2003;290:49-56.
ABSTRACT
| FULL TEXT
Outpatient adherence to beta-blocker therapy after acute myocardial infarction
Butler et al.
J Am Coll Cardiol 2002;40:1589-1595.
ABSTRACT
| FULL TEXT
Task Force #1--magnitude of the prevention problem: opportunities and challenges
Benjamin et al.
J Am Coll Cardiol 2002;40:588-603.
FULL TEXT
Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease
Gaspoz et al.
NEJM 2002;346:1800-1806.
ABSTRACT
| FULL TEXT
Supplemental Insurance and Use of Effective Cardiovascular Drugs Among Elderly Medicare Beneficiaries With Coronary Heart Disease
Federman et al.
JAMA 2001;286:1732-1739.
ABSTRACT
| FULL TEXT
Presidential address: quality of cardiovascular care in the U.S.
Beller
J Am Coll Cardiol 2001;38:587-594.
FULL TEXT
Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice
McMurray et al.
Eur J Heart Fail 2001;3:495-502.
ABSTRACT
| FULL TEXT
Increased Beta-Blocker Use After MI -- Estimated Health and Cost Benefits
Journal Watch Cardiology 2001;2001:6-6.
FULL TEXT
|
